Phio Pharmaceuticals Corp. (PHIO) shares are spiking more than 38 percent on Wednesday morning trade after the company presented key pre-clinical studies data for it Intasyl compound PH-894 aimed at melanoma cells, as an antitumor cytotoxic agent.
The first study showed that melanoma cells treated with its PH-894 compound make them more recognizable to the immune cells and thus potentially increase killing by T cells. This study supports further development of PH-894 for injectable solid tumor indications such as melanoma.
The second study demonstrates the effectiveness of PH-894 as a direct antitumor cytotoxic agent, with in vitro eliciting concentration-associated apoptosis of all human cancer cell lines tested.
The clinical-stage biotechnology company presented the data for the self-delivering RNAi therapy at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.
Currently, shares are at $1.87, up 38.96 percent from the previous close of $1.36 on a volume of 9,196,389.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.